Aptar Pharma

What Aptar Pharma does

Aptar Pharma is a business segment of AptarGroup, Inc. (NYSE: ATR), a publicly traded global supplier of drug delivery systems, components, and pharmaceutical services founded in 1942 and headquartered in Crystal Lake, Illinois, with European operations anchored in Rueil-Malmaison, France. The segment designs and manufactures proprietary delivery platforms across nasal (Unidose System, Freepod bio-based pumps, SipNose intranasal technology), injectable (PremiumCoat elastomeric plungers, Micro+ Futurity recyclable airless systems, USP <382> testing framework, aseptic RTP bags), and inhalation (Orbital DPI, Kolibri Mesh Nebuliser with guided breathing) routes, alongside HeroTracker Sense digital respiratory monitoring and digital companion solutions for wearable injectors such as Enable Injections' enFuse. Manufacturing runs across 19+ countries with 3+ billion valves produced annually and ISCC PLUS-certified sites in Switzerland and Germany supporting bio-based and recycled material production.

The company operates a B2B enterprise model serving pharmaceutical developers (primary), healthcare providers, and emergency-medicine applications including naloxone, epinephrine, and glucagon delivery. Revenue is generated through hardware sales of devices and components, professional services spanning formulation development (via subsidiary Nanopharm) and regulatory support, and recurring/subscription revenue from digital health solutions under the Aptar Digital Health subsidiary. Go-to-market relies on enterprise field sales, inside sales for quoting and account management, strategic co-development partnerships (Stallergenes Greer, Enable Injections, COVIRIX Medical, PULMOTREE, LoValTech), and channel distribution where appropriate. Pricing is non-public, quote-based enterprise contracting.

Aptar Pharma combines device expertise with formulation services (Nanopharm GMP-certified), regulatory testing support, and digital adherence platforms into an integrated 3D value proposition most explicitly positioned for GLP-1 drug delivery via autoinjectors, pen injectors, and vial systems. Recent strategic activity includes the SipNose technology acquisition (Oct 2024) extending into nose-to-brain CNS therapeutics, a new French factory announced for GLP-1 capacity (Jan 2026), and the Freepod bio-based nasal pump launch. The company is led by President and CEO Stephan B. Tanda (since 2017) and employs 10,000+ people globally, with TIME Top 100 America's Best Companies (2026, ranked 83), EcoVadis Gold, and consecutive CDP Supplier Engagement Leader recognition signaling sustained execution on innovation and ESG dimensions.

Name

Aptar Pharma

Legal name

APTARGROUP, INC.

Website

https://aptar.com

Company type

Public

Founded year

1942

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Aptar Pharma, a segment of AptarGroup (NYSE: ATR), is a global supplier of proprietary drug delivery systems — nasal, injectable, and inhalation — plus pharmaceutical services and digital health solutions serving pharmaceutical developers, healthcare providers, and emergency medicine applications across 19+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery Systems

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)

akta.pro secondary industries

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Pharmaceutical drug delivery
• Nasal spray pumps
• Injectable components
• Inhalation devices
• Digital health solutions

Headquarters

HQ city

Crystal Lake

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Delivery Devices and Components: Sale of proprietary drug delivery systems including nasal spray pumps, Unidose Systems, inhalers, and injectable components to pharmaceutical companies
2. Pharma Services: Integrated pharmaceutical services including drug formulation, regulatory support, and technical development throughout the product lifecycle
3. Digital Health Solutions: Digital patient solutions and connected device technologies that integrate with drug delivery systems for enhanced patient outcomes

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Aptar Pharma designs, manufactures, and sells proprietary drug delivery systems and components—including nasal spray pumps (Unidose System, Freepod), injectable components (elastomeric plungers, vial and syringe components), inhalation devices (dry powder inhalers, mesh nebulizers), and ophthalmic dispensers—to pharmaceutical companies. The company also provides integrated pharma services spanning formulation development, regulatory support, and digital health solutions such as connected respiratory monitoring.

Product overview

Aptar Pharma is a drug delivery solutions company offering a comprehensive portfolio of pharmaceutical delivery systems and services. The core offerings include the Unidose System (UDS) for nasal emergency therapies, Freepod bio-based nasal spray pumps, Ophthalmic Squeeze Dispensers for preservative-free eye care, and Orbital DPI technology for dry powder inhalation. The company provides integrated injectable delivery frameworks addressing USP <382> requirements, as well as aseptic transfer solutions including Rapid Transfer Port (RTP) bags for pharmaceutical manufacturing. Digital health offerings include HeroTracker Sense for respiratory medicine and digital companion solutions for wearable injectors. Supporting services include GLP-1 drug delivery solutions, FDA-funded research on inhaler propellants, and acquired technologies such as SipNose nasal delivery systems. The portfolio is complemented by manufacturing capabilities across multiple global sites including Switzerland, Germany, Brazil, and France, with ISCC PLUS certifications enabling sustainable and recycled material production.

Differentiator

Problem solved

Functional benefit

Brands

• SipNose: Nasal delivery technology assets acquired for nose-to-brain and CNS therapeutics delivery.
• Gaia
• SimpliCycle
• SimpliSqueeze
• Swimming Silicone
• Freepod
• Unidose System (UDS)
• Orbital DPI
• Kolibri
• PremiumCoat
• HeroTracker Sense

Products and services

• Unidose System (UDS) Nasal drug delivery platform with over 30 years of operational history, FDA and EMA regulatory approval, and hundreds of millions of units delivered globally. Positioned for emergency therapies including opioid overdose (naloxone), anaphylaxis (epinephrine), and hypoglycemia (glucagon), offering customizable formulations for pharmaceutical developers.
• Freepod Bio-Based Nasal Spray Pump Nasal spray pump made with mass balance bio-based resins, containing 52% ISCC Plus certified bio-based feedstock. When combined with the bottle, achieves 60% circular material content. Manufactured at Aptar's ISCC PLUS certified site in Mezzovico, Switzerland, for pharmaceutical and consumer health customers.
• Ophthalmic Squeeze Dispenser

Quantifiable outcome

• Over 30 years of FDA and EMA regulatory approval track record for Unidose System
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

• Enable InjectionscoreStrategic or Co-development Partner · 9 April 2026Strategic partnership to deliver a digital companion solution for the enFuse wearable injector system, featuring treatment data recording, injection guidance, patient-reported outcomes, and symptom tracking.
• COVIRIX MedicalcoreTechnology or Integration · 12 March 2026Technical collaboration to adapt Aptar's dry powder inhalation platform (Orbital DPI) for delivering COVIRIX Medical's broad-spectrum antiviral compounds against pandemic-potential respiratory viruses including COVID-19, influenza, and RSV.
• SipNose Nasal Delivery SystemscoreOEM/ Whitelabel/ Licensing Partner · 1 October 2024Acquisition of device technology assets from Israeli company SipNose to expand intranasal drug delivery capabilities, particularly for nose-to-brain and CNS therapeutics.
• LoValTechflagshipStrategic or Co-development Partner · 23 August 2023LoValTech and Aptar Pharma awarded France 2030 funding (8.4 million euros) for developing a nasal vaccine combined with a medical device to finalize a COVID-19 vaccine that prevents severe illness and transmission.
• Stallergenes GreercoreStrategic or Co-development Partner · 1 January 2021Partnership to develop a connected drug delivery device for allergy immunotherapy treatments, combining Stallergenes' immunotherapy expertise with Aptar's delivery technology.
• NanopharmcoreTechnology or IntegrationFormulation development services partner for the COVIRIX Medical collaboration, providing expertise in dry powder formulation development for the inhalable antiviral project.
• PULMOTREEcoreStrategic or Co-development PartnerCollaboration to develop Kolibri Mesh Nebuliser featuring guided inhalation technology with haptic feedback for precise biologic drug deposition in targeted lung regions.
• ClarinsflagshipStrategic or Co-development PartnerLong-standing partnership developing custom reloadable airless packaging solution for Clarins Total Eye Lift eye cream using patented Gaïa technology, achieving 73% material reduction per reload.
• Cheer Pack North AmericacoreChannel Partner/ Reseller/ DistributorPartnership providing SureSnap flow control valve and retaining ring for Cheer Pack N.A.'s SqueezeNSip spout, enabling leak-free dispensing for on-the-go beverages and food products.
• Ecological GroupminorStrategic or Co-development PartnerPartnership with Brazilian waste management company to collect and recycle BOPP flexible plastic film materials into post-consumer recycled resin for manufacturing closures.
• PureCycle TechnologycoreTechnology or IntegrationPreferred converting partner for Ultra-Pure Recycled PP (UPRP) applications, investigating incorporation of post-consumer recycled materials for circular economy contribution.
• EcoverminorStrategic or Co-development PartnerPartnership launched first dispensing closure in Europe made from 50% post-consumer recycled resin for Ecover washing up liquid products (2019).

Scale indicators8 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• Nemera: Nemera is a drug delivery device company offering nasal, ophthalmic, inhalation, and injectable delivery platforms. It is a directly comparable specialty drug delivery vendor competing for the same pharma partner programs across multiple delivery routes.
• Ypsomed Holding AG: Ypsomed specializes in injection systems for self-medication, including pen injectors and autoinjectors used in diabetes, GLP-1, and other injectable therapies. Direct overlap with Aptar's GLP-1 injection platform ambitions and pen injector components.
• West Pharmaceutical Services: West Pharmaceutical is the closest direct peer, providing elastomeric components, plungers, and containment systems for injectable drug delivery. Overlap with Aptar's PremiumCoat plunger line and pre-filled syringe platform is substantial, and both serve the same biologics and biosimilar pharma customers.
• Stevanato Group: Stevanato Group designs and manufactures drug containment solutions, syringes, and integrated device platforms for pharma. Like Aptar, it serves injectable and biologic delivery with proprietary components and offers both device engineering and manufacturing services.
• Gerresheimer AG: Gerresheimer is a global pharmaceutical packaging and drug delivery company producing glass primary packaging, plastic containers, and medical devices. It competes with Aptar on vial containment, syringes, and delivery systems for injectables and inhaled therapeutics.
• SCHOTT Pharma: SCHOTT Pharma manufactures primary packaging (vials, syringes, cartridges) and drug delivery solutions for the pharmaceutical industry. It is a direct comparable in containment and injectable delivery components, including services for high-value biologics.

Broad incumbents

• Amcor plc: Amcor is a global packaging giant that absorbed Berry Global in 2025, expanding its pharmaceutical and healthcare packaging footprint. It competes with Aptar in primary packaging, drug delivery components, and across the broader beauty/closures segments.
• Teleflex Medical: Teleflex is a diversified medical device manufacturer with pharmaceutical and respiratory delivery products. While broader, it overlaps with Aptar in specific delivery categories (e.g., respiratory drug delivery and specialty injectables).
• Becton, Dickinson and Company (BD): BD is a diversified medical device incumbent with major pharmaceutical systems and injectable delivery franchises (pre-filled syringes, autoinjectors, safety devices). It competes with Aptar across multiple delivery routes and is a scaled enterprise with broader portfolio reach.

Emerging players

• Catalent (Novo Holdings): Catalent is a major pharma services and drug delivery CDMO, providing softgel, inhalation, and injectable delivery solutions. Now under Novo Holdings, it competes with Aptar in formulation services and integrated drug-device development for partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/aptar
• YouTubeyoutube.com/channel/UCiJBTIPS0hWx9NCfTmbgOVA
• Facebookfacebook.com/Aptar-649067341779216
• LinkedInlinkedin.com/company/aptar
• Instagraminstagram.com/aptargroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptar Pharma